FDA advisory panel reviews peptide drug safety and regulatory standards

The FDA is convening an advisory panel to address safety and regulatory concerns surrounding the rapid proliferation of peptide-based therapeutics. The outcome will determine the approval pathway for new candidates from RevMed and GSK, while clinical data for Eli Lilly's triple-agonist therapy remains under scrutiny.